Effect of Everolimus with Low-Dose Tacrolimus on Development of New-Onset Diabetes After Transplantation and Allograft Function in Kidney Transplantation: A Multicenter, Open-Label, Randomized Trial

22 January 2021 : Original article

Hyung Duk Kim^1BEF, Ji-Yeun Chang^1CDE, Byung Ha Chung^1AB, Chan-Duck Kim^2B, Sang-Ho Lee^3B, Yeong Hoon Kim^4B, Chul Woo Yang^1ADG*

DOI: 10.12659/AOT.927984

Ann Transplant 2021; 26:e927984

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 3 Comparison of homeostatic model assessment for insulin resistance.

ITT population	EVL group	TAC group	P-value*
ITT population	N=38	N=39	P-value*

Baseline	1.26±0.89	1.12±0.39	0.6176
12 months	1.29±0.91	1.30±0.56	0.5376
Mean change from baseline	0.03±0.99	0.18±0.57	0.2688
p-value^**	0.9238	0.0532

Baseline	94.29±42.53	85.64±27.58	0.5309
12 months	97.46±44.74	92.45±31.16	0.9756
Mean change from baseline	3.17±24.31	6.81±26.02	0.3228
p-value^**	0.5915	0.1105
	N=27	N=38
HOMA-IR
Baseline	1.13±0.40	1.11±0.40	0.8593
12 months	1.26±0.93	1.30±0.56	0.3756
Mean change from baseline	0.13±1.05	0.19±0.57	0.3213
p-value^**	0.7792	0.0492

Baseline	89.96±30.85	86.11±27.80	0.6006
12 months	90.82±28.23	93.47±30.91	0.7244
Mean change from baseline	0.86±26.05	7.37±26.13	0.3253
p-value^**	0.7792	0.0905
^* Wilcoxon’s rank sum test; ^** Wilcoxon’s signed rank test. HOMA-IR=fasting insulin (uU/mL)×fasting glucose (mg/dL)/405. HOMA-%B=(20×fasting insulin (uU/mL))/(fasting glucose (mg/dL)/18–3.5). Discrete variables are presented with n (%), and continuous variables with normal distributions are presented with mean±S.D. HOMA – homeostatic model assessment; IR – insulin resistance.

Back to the Article